KR102630013B1 - 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체 - Google Patents

항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체 Download PDF

Info

Publication number
KR102630013B1
KR102630013B1 KR1020187006431A KR20187006431A KR102630013B1 KR 102630013 B1 KR102630013 B1 KR 102630013B1 KR 1020187006431 A KR1020187006431 A KR 1020187006431A KR 20187006431 A KR20187006431 A KR 20187006431A KR 102630013 B1 KR102630013 B1 KR 102630013B1
Authority
KR
South Korea
Prior art keywords
formula
compound
pharmaceutically acceptable
compound according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187006431A
Other languages
English (en)
Korean (ko)
Other versions
KR20180039666A (ko
Inventor
르로이 타운센드
존 드라크
로이 더블유. 웨어
존 헨리 3세 보우거
라마머티 브이 에스 찬갈바라
아론 레이 다우니
어니스트 랜들 주니어 라니어
앤드루 루이스 맥아이버
브래들리 데이비드 로버트슨
딘 월리스 셀레세트
피로즈 베럼 세트나
Original Assignee
키메릭스 인크.
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키메릭스 인크., 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 키메릭스 인크.
Publication of KR20180039666A publication Critical patent/KR20180039666A/ko
Application granted granted Critical
Publication of KR102630013B1 publication Critical patent/KR102630013B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020187006431A 2015-08-06 2016-08-08 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체 Active KR102630013B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562202010P 2015-08-06 2015-08-06
US62/202,010 2015-08-06
GB201606645 2016-04-15
GB1606645.8 2016-04-15
PCT/US2016/046056 WO2017024310A1 (en) 2015-08-06 2016-08-08 Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents

Publications (2)

Publication Number Publication Date
KR20180039666A KR20180039666A (ko) 2018-04-18
KR102630013B1 true KR102630013B1 (ko) 2024-01-25

Family

ID=57943734

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006431A Active KR102630013B1 (ko) 2015-08-06 2016-08-08 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체

Country Status (11)

Country Link
US (6) US9708359B2 (https=)
EP (1) EP3331895B1 (https=)
JP (1) JP2018523665A (https=)
KR (1) KR102630013B1 (https=)
CN (1) CN108026136A (https=)
AU (1) AU2016301188A1 (https=)
BR (1) BR112018002399A2 (https=)
EA (1) EA201890454A1 (https=)
MX (1) MX2018001073A (https=)
PH (1) PH12018500263A1 (https=)
WO (1) WO2017024310A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
JP6584521B2 (ja) * 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
TWI767937B (zh) * 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
CA3080896A1 (en) 2017-10-31 2019-05-09 Yamasa Corporation Nucleoside derivative and use thereof
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
EP3762372A4 (en) * 2018-03-07 2021-12-08 Emory University THERAPEUTIC 4'-HALOGENIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES IN RELATION THEREOF
AU2020334152A1 (en) 2019-08-22 2022-03-24 Emory University Nucleoside prodrugs and uses related thereto
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
AU2021235223A1 (en) * 2020-03-09 2022-09-29 Denis Barritault Composition for the treatment of lesions of the respiratory system
US20230233591A1 (en) * 2020-04-14 2023-07-27 Oyagen, Inc. Method for treating poxviridae infections
AU2021330835B2 (en) * 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
US20240207299A1 (en) * 2021-03-29 2024-06-27 Chimerix, Inc. Pyrrolopyrimidine nucleosides for treating or preventing a sars-cov-2 infection
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN121358746A (zh) * 2023-04-28 2026-01-16 斯克瑞普斯研究所 作为抗病毒剂的4'-取代的核苷和核苷酸
EP4553080A1 (en) * 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067409A1 (en) 2007-11-20 2009-05-28 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
US3423398A (en) 1965-05-10 1969-01-21 Pfizer & Co C Sangivamycin and derivatives thereof
US4140851A (en) 1977-11-21 1979-02-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
JPS61189225A (ja) 1985-02-15 1986-08-22 Airin:Kk 抗アレルギ−剤
US4892865A (en) 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
WO1992005200A1 (en) 1990-09-18 1992-04-02 Chemex Pharmaceuticals, Inc. Xenobiotic-antibody conjugates
JPH06510020A (ja) 1991-03-29 1994-11-10 ユニバーシティ・オブ・フロリダ 混成リン酸エステル誘導体を経た標的への薬剤供給
ATE147386T1 (de) 1991-08-12 1997-01-15 Takeda Chemical Industries Ltd Kondensierte pyrimidinderivate, ihre herstellung und ihre verwendung als antitumormittel
CA2129105A1 (en) 1992-02-12 1993-08-19 Michael J. Conrad Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
EP0684953A4 (en) 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH07124252A (ja) 1993-11-07 1995-05-16 Masashi Funayama 化学療法剤を固定化した不溶性担体を用いた、負に帯電した 生理活性物質の吸着、分離および定量方法。
JPH10501532A (ja) 1994-06-09 1998-02-10 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
US5554608A (en) 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
DE69725440T2 (de) 1996-06-06 2004-07-22 Novartis Ag 2-substituierte nukleosid- und oligonukleotid- derivate
US5955446A (en) 1997-01-16 1999-09-21 Pentose Pharmaceuticals, Inc. Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
US6468991B1 (en) 1997-01-16 2002-10-22 Cyclis Pharmaceuticals, Inc. Method of treating rhinoviral infections
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
AU1929801A (en) 1999-12-16 2001-06-25 Alcon Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
KR100385281B1 (ko) 2000-02-15 2003-05-23 이승기 새로운 세포 주기 조절 인자 억제제
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
WO2002057425A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
US20020127593A1 (en) 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
AU2002329970A1 (en) 2001-09-04 2003-03-18 Isis Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2002364216A1 (en) * 2001-12-21 2003-07-15 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
JP2005527499A (ja) 2002-02-13 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
FR2836996A1 (fr) 2002-03-05 2003-09-12 Centre Nat Rech Scient PRECURSEURS DE TRACEURS IMMUNOLOGIQUES NON-PEPTIDIQUES COMPRENANT UN MOTIF TYROSYL-(X)n-LYSINE-(X)n-TYROSINE, PROCEDE DE PREPARATION ET LEURS APPLICATIONS
FR2836995B1 (fr) 2002-03-05 2006-09-22 Centre Nat Rech Scient Utilisation de derives de nucleosides comportant un groupement citrate pour la production d'anticorps ayant une affinite pour des nucleosides triphosphorylees et leurs applications
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
EP1572945A2 (en) 2002-06-27 2005-09-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2005533108A (ja) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
AU2003279797B2 (en) 2002-09-30 2009-10-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
JP5046219B2 (ja) 2002-10-31 2012-10-10 リガンド・ファーマシューティカルズ・インコーポレイテッド １，３−プロパン−１−アリールジオールの新規環状リン酸ジエステルおよびそのプロドラッグへの使用
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
US20040175384A1 (en) 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
CA2545697C (en) 2003-11-14 2016-12-20 Richard Mulligan Self-cleaving ribozymes and uses thereof
EP1685127A1 (en) 2003-11-21 2006-08-02 The University of Connecticut Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
EP1773355B1 (en) 2004-06-24 2014-06-25 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
JP5710855B2 (ja) 2005-02-02 2015-04-30 ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 神経線維腫の局所治療
EP1876894A1 (en) 2005-04-26 2008-01-16 The Board of Trustees of the University of Illinois Nucleoside compounds and methods of use thereof
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
BRPI0615307A2 (pt) 2005-08-25 2009-08-04 Schering Corp agonistas de adrenorreceptor alfa2c
JP2007124252A (ja) 2005-10-27 2007-05-17 Sony Corp 放送受信装置と放送受信方法およびプログラム
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CN1923171B (zh) 2006-02-24 2010-05-19 济南康泉医药科技有限公司 同载抗癌抗生素及其增效剂的复方抗癌药物缓释剂
CN1923173B (zh) 2006-02-24 2010-05-19 济南康泉医药科技有限公司 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008021981A2 (en) 2006-08-09 2008-02-21 Nexgenix Pharmaceuticals, Llc. Local treatment of epidermal and dermal hyperproliferative lesions
WO2008079980A1 (en) 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
TW200838550A (en) 2007-02-09 2008-10-01 Novartis Ag Organic compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2214670A2 (en) 2007-11-02 2010-08-11 Taiga Biotechnologies, Inc. Compounds for treating abnormal cellular proliferation
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010015643A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
US8785446B2 (en) 2009-01-17 2014-07-22 Children's Medical Center Corporation Treating post-seizure patients
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8642602B2 (en) 2009-02-04 2014-02-04 University Of Georgia Research Foundation, Inc. Method of inhibiting fibrogenesis and treating fibrotic disease
JP2012517443A (ja) * 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
WO2011041385A2 (en) 2009-09-29 2011-04-07 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
BR112012009215A2 (pt) 2009-10-19 2019-09-24 Synta Pharmaceuticals Corp "terapia combinada contra o cancer com compostos inibidores de hsp90"
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
EP2516428A1 (en) 2009-12-23 2012-10-31 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
WO2011079103A1 (en) 2009-12-23 2011-06-30 Sanofi Spiropiperidine benzylamines as beta-tryptase inhibitors
WO2011088137A2 (en) 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
CN102191233B (zh) 2010-03-04 2014-06-04 中国人民解放军军事医学科学院毒物药物研究所 新颖的10-23脱氧核酶类似物及其用途
CN102869254A (zh) 2010-04-16 2013-01-09 安龙制药公司 腺嘌呤核苷酸类似物聚合共轭物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
GB201107768D0 (en) 2011-05-10 2011-06-22 Univ Manchester Riboswitches
CN102286048A (zh) 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
WO2013071415A1 (en) 2011-11-15 2013-05-23 University Health Network Targeting the rb pathway for the prevention of cancer
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2992107B1 (en) 2013-04-29 2019-12-11 Plasmia Biotech, S.L. Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067409A1 (en) 2007-11-20 2009-05-28 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., 2014, 57, 1097-1110.

Also Published As

Publication number Publication date
BR112018002399A2 (pt) 2018-09-25
MX2018001073A (es) 2018-06-12
EP3331895B1 (en) 2020-07-29
US11981700B2 (en) 2024-05-14
WO2017024310A1 (en) 2017-02-09
CN108026136A (zh) 2018-05-11
CA2992278A1 (en) 2017-02-09
US10407457B2 (en) 2019-09-10
US9701706B2 (en) 2017-07-11
AU2016301188A1 (en) 2018-02-15
US10941175B2 (en) 2021-03-09
US20170253628A1 (en) 2017-09-07
PH12018500263A1 (en) 2018-08-13
US20200199167A1 (en) 2020-06-25
EP3331895A1 (en) 2018-06-13
US20220002335A1 (en) 2022-01-06
US20170044202A1 (en) 2017-02-16
US9708359B2 (en) 2017-07-18
KR20180039666A (ko) 2018-04-18
US20250084119A1 (en) 2025-03-13
JP2018523665A (ja) 2018-08-23
EA201890454A1 (ru) 2018-07-31
US20170137454A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
KR102630013B1 (ko) 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체
RU2599013C2 (ru) Способы и композиции для ингибирования полимеразы
CA3139977A1 (en) Peptidomimetics for the treatment of coronavirus and picornavirus infections
CA2692460A1 (en) Hiv reverse transcriptase inhibitors
CN117362344A (zh) 一类磷酸酯类化合物、其制备方法及应用
US6596771B2 (en) Drugs for treating viral infections
CA2992278C (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
EP3077403A1 (en) Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
EP4292658A2 (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
ES2829254T3 (es) Nucleósidos de pirrolopirimidina y análogos de los mismos útiles como agentes antivíricos
US20190201352A1 (en) Design, synthesis and methods of use of acyclic flexmier nucleoside analogues having anti-coronavirus activity
WO2021231784A1 (en) Perk inhibiting imidazolopyrazine compounds
CA3090294C (en) Methods of preparing tecovirimat
WO2011071981A2 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
CN108201539B (zh) 联苯核苷氨基磷酸酯化合物的应用
EP4103567B1 (en) Spirocyclic inhibitors of hepatitis b virus
HK40104785A (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2021231782A1 (en) Perk inhibitors for treating viral infections
WO2021231788A1 (en) Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
EP3985010A1 (en) Spirocyclic inhibitors of hepatitis b virus
EP4093401A1 (en) Salicylamide derivatives and related methods of making

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210726

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230412

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231114

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240123

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240123

End annual number: 3

Start annual number: 1

PG1601 Publication of registration